ZBH · News · 20260805N
Guidance / Outlook
ZIMMER BIOMET HOLDINGS, INC. · 2026-08-05 · Importance 57 · Surprise 60 · In source text
Zimmer Biomet raised its full-year 2026 revenue and adjusted EPS outlook after the second-quarter beat. The company projected full-year adjusted EPS of $8.47 to $8.59 in reported coverage. The guidance increase reflects stronger U.S. hip and technology performance, new-product momentum, and better-than-expected execution of the sales-force transformation. Management also cited continued investment in digital health, robotics, and data-driven surgical solutions as longer-term growth drivers.
Key facts
- Company provided a full-year adjusted EPS projection of $8.47 to $8.59 source
- Company raised its full-year 2026 outlook / lifted 2026 view after Q2 beat source
- Company raised its full-year revenue and adjusted EPS guidance following Q2 results source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | unclear | probable | — | Company provided a full-year adjusted EPS projection of $8.47 to $8.59 |
| revenue | positive | probable | — | Company raised its full-year revenue and adjusted EPS guidance following Q2 results |
| net_income | positive | probable | — | Company raised its full-year revenue and adjusted EPS guidance following Q2 results |